Entity

GLP-1

GLP-1 — glucagon-like peptide-1 (agonists). The drug class behind Ozempic and Wegovy — obesity and diabetes treatments reshaping pharma pipelines and food-industry forecasts.

As of 19 Oct 2026Last evidence 19 Oct 2026

What is happening now

  • 2026 fda approved weight loss drug retatrutide approval status

    Reported claim · first reported 13 Oct 2026 · 1 claim · best-carried claim: 4 separate publishers

All 1 event and claims involving GLP-1

What changed

  • Attention Rising: 40 mentions on 19 Oct 2026, against 13 on 28 Sept 2026 (+208%).
  • State No change in coverage state or wire tier recorded since 9 Oct 2026.
  • Claims No claim first reported since 18 Oct 2026.

How well we know this

438 documents · 119 publishers · 9% contain a typed assertion · last evidence 19 Oct 2026

  • Gap: assertion coverage 0.087: about 91% of mentions carry no typed assertion
  • Gap: 4 receipts withheld: no source link (the same rule the topic record applies)

In this snapshot’s daily coverage:

Reported alongside GLP-1

Names most often reported alongside it; bigger circles and heavier lines mean more shared documents. A dashed circle has no page of its own yet.

Eli LillyAIZepboundChinaUnited States
  • FDA · 114 shared documents · no page of its own yet
  • Eli Lilly · 110 shared documents
  • Glp-1s · 100 shared documents · no page of its own yet
  • AI · 92 shared documents
  • Novo Nordisk · 71 shared documents · no page of its own yet
  • Mounjaro · 62 shared documents · no page of its own yet
  • Zepbound · 56 shared documents
  • China · 54 shared documents
  • Clinical Trial · 48 shared documents · no page of its own yet
  • United States · 48 shared documents

Story momentum

Rising

The word compares 40 mentions on 19 Oct 2026 with 13 on 28 Sept 2026 (+208%); a change of less than 8% either way reads Steady.

Daily mentions +471% from 4 Sept 2026 to 19 Oct 2026, between 4 and 51 a day

How often tracked coverage mentions GLP-1, day by day.

Market price, cited

Not priced yet

No open prediction market prices a question materially about GLP-1 yet. Ask about GLP-1

No market price on file: no prediction market prices a question about this name yet

Coverage volume and market price are separate measures.

For developers

This page is also an object: GET https://sigb.ai/api/v1/node/e/6d911ae375a0bffac4f2f4c7 returns the same record as sb.node.v1. Or call the get_entity MCP tool at https://sigb.ai/api/mcp with name glp-1.

{
  "name": "glp-1",
  "label": "GLP-1",
  "asOf": "2026-10-19",
  "mentions": 60,
  "outlets": 37,
  "domains": 5,
  "node": {
    "id": "sb:e/6d911ae375a0bffac4f2f4c7",
    "schema": "sb.node.v1",
    "rest": "https://sigb.ai/api/v1/node/e/6d911ae375a0bffac4f2f4c7",
    "knowledgeCutoff": "2026-10-19T19:02:44.993471+00:00",
    "snapshot": "this deploy's committed data files (commit not exposed in this runtime)"
  },
  "coverageTrend": "rising",
  "history": {
    "since": "2026-10-09T13:18:22.628694+00:00",
    "changes": 0
  },
  "whereFrom": {
    "level": "counts",
    "label": "60 mentions across 5 domains",
    "children": [
      {
        "level": "reports",
        "label": "6 reports drawn on this page, each with its link",
        "children": {
          "count": 6,
          "unfold": "expand=+1"
        }
      },
      {
        "level": "domains",
        "label": "5 coverage domains",
        "children": {
          "count": 5,
          "unfold": "expand=+1"
        }
      },
      {
        "level": "not shown",
        "label": "The other 54 mentions",
        "edge": "counted daily from tracked coverage; single mentions are not listed one by one"
      }
    ]
  }
}

The figures on this page, as data. The tool returns the full entity record.

Events involving GLP-1

Most-reported first, then newest. Registered events come from the event record; reported events are groups of claims about one occurrence. Claims are grouped when they were first reported within 2 days of each other and either name at least 2 of the same people, places or things besides this one, or share at least 25% of their wording. Each claim keeps its own record.

  • 2026 fda approved weight loss drug retatrutide approval status

    Reported claim · first reported 13 Oct 2026 · 1 claim · best-carried claim: 4 separate publishers

    could not check

Walk the record from GLP-1

Open where it comes from, follow a claim or a related name, and use the trail to come back. Every step says what it is, how it stands and when. Machines read the same record.

GLP-1

Entity.

Evidence
438 documents · 119 separate publishers · a mention shows the name is in use, not that any claim about it is true
Standing
A name from our starting list; its record is kept up to date automatically from coverage
Time
first seen 6 Apr 2026, last seen 19 Oct 2026
Measured
9% of mentions say something specific about it; the rest only name it
As of
19 Oct 2026
11 links from here

Who it moves with: the 10 names are in the map above.

What is claimed about it (1)

  • Could not check: We could not count this claim's sources, so we do not say how well it is supported.

Situations it is named in (0)

none on file at this cutoff

For machines: this record as JSON

Watch this

What the coverage says

Recent reporting that names GLP-1, newest first. Open any row to follow it to the original article.

What it connects to

Related records.

Pull a thread

Recorded history

No change in coverage state or wire tier recorded since 9 Oct 2026.

Ask about GLP-1Watch GLP-1

Story momentum counts mentions in tracked coverage. Prices are the market’s own, cited with the venue. Informational only, not advice. As of 19 Oct 2026.